Why Is ACADIA PHARMACEUTICA (ACAD) Stock Moving Today?

ACAD stock closed down 5.70% at $20.92 on Friday, marking one of the largest moves in its recent trading pattern. The decline follows a series of analyst actions that reduced price targets in response to updated trial data for remlifanserin. Analysts at multiple firms have revised their expectations downward, contributing to a broader reassessment of the stock’s near-term potential.

What Happened

Analysts from H.C. Wainwright, Needham, Deutsche Bank, BMO Capital, and Citizens all cut their price targets for ACAD in the past 36 hours. These moves followed the RADIANT trial update, which has prompted a reevaluation of the drug’s development timeline and commercial prospects. Despite some firms maintaining a Buy or Outperform rating, the downward revision in price targets has weighed on investor sentiment. The stock opened at $22.25 but quickly fell throughout the session, hitting an intraday low of $20.88 before closing near that level. The volume of 0.8 million shares was above the 3-month average, indicating increased attention to the stock.

What The Data Shows

ACAD has traded within a 52-week range of $19.69 to $30.96, and the stock has fallen 13.0% over the last eight sessions. The company has a market cap of $4.4 billion and a P/E ratio of 10.1, with revenue growing 11.8% in the trailing twelve months. Recent insider transactions include three sales totaling $1.3 million in the last 90 days. Unusual options activity was noted, with a call option print of $165,000. The stock also printed 32 fresh 52-week lows on September 25, indicating heightened bearish pressure.

What To Watch

The stock is set to continue under analyst scrutiny as more firms may adjust their outlooks. Investors should monitor coverage breadth and any further updates from Acadia on remlifanserin’s development.